ACADEMIA

Osteoporosis Experts Express “Shock” at Discontinuation of Development of Odanacatib

October 7, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Experts of osteoporosis treatments lamented the discontinuation of development of odanacatib, which was expected to be safer and more effective than existing drugs, at the annual meeting of the Japan Osteoporosis Society (JOS). Odanacatib, a cathepsin K inhibitor, was being…

To read the full story

Merck Ditches Osteoporosis Med Odanacatib from Global Pipelines
September 6, 2016

ACADEMIA

Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…